JP2025517634A - 上皮増殖因子受容体阻害剤の塩形態及び結晶形態 - Google Patents
上皮増殖因子受容体阻害剤の塩形態及び結晶形態 Download PDFInfo
- Publication number
- JP2025517634A JP2025517634A JP2024564833A JP2024564833A JP2025517634A JP 2025517634 A JP2025517634 A JP 2025517634A JP 2024564833 A JP2024564833 A JP 2024564833A JP 2024564833 A JP2024564833 A JP 2024564833A JP 2025517634 A JP2025517634 A JP 2025517634A
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- mesylate salt
- ray powder
- powder diffraction
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338371P | 2022-05-04 | 2022-05-04 | |
| US63/338,371 | 2022-05-04 | ||
| PCT/US2023/020925 WO2023215431A1 (en) | 2022-05-04 | 2023-05-04 | Salt and crystal forms of an epidermal growth factor receptor inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517634A true JP2025517634A (ja) | 2025-06-10 |
| JP2025517634A5 JP2025517634A5 (enExample) | 2026-05-12 |
Family
ID=86688767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024564833A Pending JP2025517634A (ja) | 2022-05-04 | 2023-05-04 | 上皮増殖因子受容体阻害剤の塩形態及び結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250282761A1 (enExample) |
| EP (1) | EP4519254A1 (enExample) |
| JP (1) | JP2025517634A (enExample) |
| KR (1) | KR20250012078A (enExample) |
| CN (1) | CN119923392A (enExample) |
| AU (1) | AU2023265064A1 (enExample) |
| CA (1) | CA3251624A1 (enExample) |
| IL (1) | IL316663A (enExample) |
| MX (1) | MX2024013485A (enExample) |
| TW (1) | TW202409016A (enExample) |
| UY (1) | UY40256A (enExample) |
| WO (1) | WO2023215431A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097270A1 (en) * | 2022-11-01 | 2024-05-10 | Blueprint Medicines Corporation | Egfr inhibitors for treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113493419A (zh) * | 2020-03-18 | 2021-10-12 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| CN113493420B (zh) * | 2020-03-18 | 2025-04-25 | 南京迈晟科技有限责任公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| IL302457A (en) * | 2020-10-30 | 2023-06-01 | Blueprint Medicines Corp | Pyrimidine compounds, preparations and their medical applications |
| CA3196857A1 (en) * | 2020-10-30 | 2022-05-05 | Gurulingappa Hallur | Pyrimidine compounds, compositions, and medicinal applications thereof |
-
2023
- 2023-05-04 EP EP23728478.1A patent/EP4519254A1/en active Pending
- 2023-05-04 US US18/862,859 patent/US20250282761A1/en active Pending
- 2023-05-04 CN CN202380051632.8A patent/CN119923392A/zh active Pending
- 2023-05-04 IL IL316663A patent/IL316663A/en unknown
- 2023-05-04 TW TW112116649A patent/TW202409016A/zh unknown
- 2023-05-04 UY UY0001040256A patent/UY40256A/es not_active Application Discontinuation
- 2023-05-04 AU AU2023265064A patent/AU2023265064A1/en active Pending
- 2023-05-04 WO PCT/US2023/020925 patent/WO2023215431A1/en not_active Ceased
- 2023-05-04 KR KR1020247040290A patent/KR20250012078A/ko active Pending
- 2023-05-04 CA CA3251624A patent/CA3251624A1/en active Pending
- 2023-05-04 JP JP2024564833A patent/JP2025517634A/ja active Pending
-
2024
- 2024-10-31 MX MX2024013485A patent/MX2024013485A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202409016A (zh) | 2024-03-01 |
| AU2023265064A1 (en) | 2024-11-14 |
| US20250282761A1 (en) | 2025-09-11 |
| MX2024013485A (es) | 2024-12-06 |
| IL316663A (en) | 2024-12-01 |
| WO2023215431A1 (en) | 2023-11-09 |
| EP4519254A1 (en) | 2025-03-12 |
| CN119923392A (zh) | 2025-05-02 |
| KR20250012078A (ko) | 2025-01-23 |
| CA3251624A1 (en) | 2023-11-09 |
| UY40256A (es) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7383652B2 (ja) | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 | |
| TWI753918B (zh) | 作為ｊａｋ抑制劑的吡咯並嘧啶化合物的結晶 | |
| US9879008B2 (en) | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof | |
| US9630952B2 (en) | Crystalline forms of afatinib di-maleate | |
| CN119654319A (zh) | 一种cdk抑制剂及其磷酸盐的多晶型 | |
| EP3986897A1 (en) | Egfr inhibitor for the treatment of cancer | |
| WO2019042444A1 (zh) | 一类抑制并降解酪氨酸蛋白激酶alk的化合物 | |
| JP2011515370A (ja) | ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態 | |
| WO2016011979A1 (zh) | 2，4-二取代7H-吡咯并[2，3-d]嘧啶衍生物、其制法与医药上的用途 | |
| CA3198096A1 (en) | Aryl derivatives for treating trpm3 mediated disorders | |
| TW202136263A (zh) | 新穎 egfr 抑制劑 | |
| CN111763215A (zh) | 一种具有含氮杂环结构的化合物及其制备方法和用途 | |
| ES2814499T3 (es) | Formas en estado sólido de sales de Nilotinib | |
| CN112119074A (zh) | Egfr抑制剂 | |
| CN113773305A (zh) | 一种氨基嘧啶衍生物及其作为egfr酪氨酸激酶抑制剂的应用 | |
| WO2019196938A1 (zh) | 喹唑啉类化合物作为egfr三突变抑制剂及其应用 | |
| KR20200032152A (ko) | N-페닐-2-아미노피리미딘 화합물의 결정형과 염형, 및 이의 제조 방법 | |
| US20250282761A1 (en) | Salt and crystal forms of an epidermal growth factor receptor inhibitor | |
| JP2021529175A (ja) | Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用 | |
| CN109593102A (zh) | 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型 | |
| JP7712994B2 (ja) | 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 | |
| KR20250038235A (ko) | 고체 형태의 jak 억제제 및 이의 제조 공정 | |
| TW202311267A (zh) | 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用 | |
| JP2023505254A (ja) | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドを製造するための方法 | |
| WO2019170086A1 (zh) | 一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260428 |